Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW0311 vs Prolia in Postmenopausal Women With Osteoporosis
NCT06804590Phase 3Completed
- Sponsor
- Mabwell
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 9MW0311 in osteoporosis (2 arms), sponsored by Mabwell. Primary endpoint: Percent Change From Baseline in lumbar spine Bone Mineral Density at 12 months. Started Nov 2024; status: completed.
02
Drugs
9MW0311
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06804590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804590.